Quintet Private Bank Europe S.A. Sells 2,779 Shares of Bristol-Myers Squibb (NYSE:BMY)

Quintet Private Bank Europe S.A. lessened its position in Bristol-Myers Squibb (NYSE:BMY) by 5.0% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 52,578 shares of the biopharmaceutical company’s stock after selling 2,779 shares during the quarter. Quintet Private Bank Europe S.A.’s holdings in Bristol-Myers Squibb were worth $3,207,000 at the end of the most recent reporting period.

Several other institutional investors also recently added to or reduced their stakes in BMY. Pinney & Scofield Inc. purchased a new stake in Bristol-Myers Squibb during the 4th quarter worth approximately $25,000. Park Square Financial Group LLC acquired a new position in Bristol-Myers Squibb during the fourth quarter worth $26,000. Fairway Wealth LLC purchased a new stake in shares of Bristol-Myers Squibb during the fourth quarter worth $28,000. Transce3nd LLC purchased a new stake in shares of Bristol-Myers Squibb during the fourth quarter worth $28,000. Finally, Global Wealth Strategies & Associates grew its holdings in shares of Bristol-Myers Squibb by 137.5% in the first quarter. Global Wealth Strategies & Associates now owns 475 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 275 shares during the period. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Insiders Place Their Bets

In other Bristol-Myers Squibb news, EVP Samit Hirawat acquired 4,250 shares of the firm’s stock in a transaction that occurred on Friday, April 25th. The shares were acquired at an average cost of $47.58 per share, for a total transaction of $202,215.00. Following the transaction, the executive vice president now directly owns 83,513 shares of the company’s stock, valued at approximately $3,973,548.54. This represents a 5.36% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders own 0.09% of the company’s stock.

Bristol-Myers Squibb Stock Up 1.0%

BMY stock opened at $50.68 on Friday. The company has a current ratio of 1.25, a quick ratio of 1.15 and a debt-to-equity ratio of 2.90. Bristol-Myers Squibb has a twelve month low of $39.35 and a twelve month high of $63.33. The company’s 50 day moving average is $48.78 and its two-hundred day moving average is $54.83. The stock has a market cap of $103.14 billion, a P/E ratio of -11.47, a PEG ratio of 2.07 and a beta of 0.38.

Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.50 by $0.30. The business had revenue of $11.20 billion for the quarter, compared to analyst estimates of $10.77 billion. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. The company’s revenue for the quarter was down 5.6% compared to the same quarter last year. During the same period last year, the firm posted ($4.40) earnings per share. Research analysts expect that Bristol-Myers Squibb will post 6.74 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the stock. Cantor Fitzgerald reissued a “neutral” rating and issued a $55.00 price objective on shares of Bristol-Myers Squibb in a report on Tuesday, April 22nd. William Blair reaffirmed a “market perform” rating on shares of Bristol-Myers Squibb in a research report on Friday, April 25th. UBS Group decreased their target price on shares of Bristol-Myers Squibb from $60.00 to $54.00 and set a “neutral” rating on the stock in a research report on Friday, April 11th. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $55.00 target price (down previously from $67.00) on shares of Bristol-Myers Squibb in a research report on Tuesday, April 8th. Finally, Piper Sandler initiated coverage on shares of Bristol-Myers Squibb in a research report on Tuesday, April 22nd. They issued an “overweight” rating and a $65.00 target price on the stock. Two analysts have rated the stock with a sell rating, thirteen have issued a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $58.00.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.